adenine has been researched along with Opportunistic Infections in 13 studies
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice." | 4.02 | Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. ( Busca, A; Candoni, A; Cattaneo, C; Dargenio, M; Facchinelli, D; Fanci, R; Farina, F; Laurenti, L; Lessi, F; Marchesi, F; Marchesini, G; Nadali, G; Pagano, L; Picardi, M; Prezioso, L; Spolzino, A; Tisi, MC; Trastulli, F; Verga, L; Visentin, A, 2021) |
| "Opportunistic infections in chronic lymphocytic leukemia (CLL) have been described in clinical trials, single-center studies, and case reports." | 1.62 | A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. ( Aspelund, T; Björkholm, M; Gíslason, GK; Gottfreðsson, M; Kristinsson, SY; Landgren, O; Rögnvaldsson, S; Steingrímsson, V; Turesson, I; Þorsteinsdóttir, S, 2021) |
| "Invasive bacterial infections developed in 23 (53." | 1.48 | Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. ( Cohen, N; Hohl, TM; Palomba, ML; Redelman-Sidi, G; Seo, SK; Taur, Y; Varughese, T, 2018) |
| "These results indicate that MAIDS can be used as a model for evaluating antivirals in an immunocompromised host, and suggest that both PMEA and HPMPC may be useful in the treatment of opportunistic CMV and HSV-1 infections." | 1.28 | Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. ( De Castro, LM; De Clercq, E; Gangemi, JD; Ghaffar, A; Kern, ER; Mayer, EP; Vogt, PE, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Marchesini, G | 1 |
| Nadali, G | 1 |
| Facchinelli, D | 1 |
| Candoni, A | 1 |
| Cattaneo, C | 1 |
| Laurenti, L | 1 |
| Fanci, R | 1 |
| Farina, F | 1 |
| Lessi, F | 1 |
| Visentin, A | 1 |
| Marchesi, F | 1 |
| Prezioso, L | 1 |
| Spolzino, A | 1 |
| Tisi, MC | 1 |
| Trastulli, F | 1 |
| Picardi, M | 1 |
| Verga, L | 1 |
| Dargenio, M | 1 |
| Busca, A | 1 |
| Pagano, L | 1 |
| Steingrímsson, V | 1 |
| Gíslason, GK | 1 |
| Þorsteinsdóttir, S | 1 |
| Rögnvaldsson, S | 1 |
| Gottfreðsson, M | 1 |
| Aspelund, T | 1 |
| Turesson, I | 1 |
| Björkholm, M | 1 |
| Landgren, O | 1 |
| Kristinsson, SY | 1 |
| Winqvist, M | 1 |
| Palma, M | 1 |
| Heimersson, K | 1 |
| Mellstedt, H | 1 |
| Österborg, A | 1 |
| Lundin, J | 1 |
| Saluzzo, S | 1 |
| Layer, F | 1 |
| Stingl, G | 1 |
| Stary, G | 1 |
| Gaye, E | 1 |
| Le Bot, A | 1 |
| Talarmin, JP | 1 |
| Le Calloch, R | 1 |
| Belaz, S | 1 |
| Dupont, M | 1 |
| Tattevin, P | 1 |
| Varughese, T | 1 |
| Taur, Y | 1 |
| Cohen, N | 1 |
| Palomba, ML | 1 |
| Seo, SK | 1 |
| Hohl, TM | 1 |
| Redelman-Sidi, G | 1 |
| Grossi, O | 1 |
| Pineau, S | 1 |
| Sadot-Lebouvier, S | 1 |
| Hay, B | 1 |
| Delaunay, J | 1 |
| Miailhe, AF | 1 |
| Bretonnière, C | 1 |
| Jeddi, F | 1 |
| Lavergne, RA | 1 |
| Le Pape, P | 1 |
| Rogers, KA | 1 |
| Mousa, L | 1 |
| Zhao, Q | 1 |
| Bhat, SA | 1 |
| Byrd, JC | 1 |
| El Boghdadly, Z | 1 |
| Guerrero, T | 1 |
| Levine, LB | 1 |
| Lucas, F | 1 |
| Shindiapina, P | 1 |
| Sigmund, AM | 1 |
| Sullivan, M | 1 |
| Wiczer, TE | 1 |
| Woyach, JA | 1 |
| Awan, FT | 1 |
| Bond, DA | 1 |
| Alinari, L | 1 |
| Maddocks, K | 1 |
| Chan, TS | 1 |
| Au-Yeung, R | 1 |
| Chim, CS | 1 |
| Wong, SC | 1 |
| Kwong, YL | 1 |
| De Castro, LM | 1 |
| Kern, ER | 1 |
| De Clercq, E | 3 |
| Ghaffar, A | 1 |
| Mayer, EP | 1 |
| Vogt, PE | 1 |
| Gangemi, JD | 2 |
| Egberink, H | 1 |
| Borst, M | 1 |
| Niphuis, H | 1 |
| Balzarini, J | 2 |
| Neu, H | 1 |
| Schellekens, H | 1 |
| Horzinek, M | 1 |
| Koolen, M | 1 |
| Cozens, RM | 1 |
| Hochkeppel, HK | 1 |
1 review available for adenine and Opportunistic Infections
| Article | Year |
|---|---|
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic | 2019 |
1 trial available for adenine and Opportunistic Infections
| Article | Year |
|---|---|
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Alemtuzumab; Antineoplastic Combined Chemotherap | 2018 |
11 other studies available for adenine and Opportunistic Infections
| Article | Year |
|---|---|
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Bacterial Infections; Case-Co | 2021 |
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
Topics: Adenine; Aged; Cross Infection; Humans; Incidence; Inpatients; Leukemia, Lymphocytic, Chronic, B-Cel | 2021 |
Staphylococcal Scalded Skin Syndrome Caused by a Rare Variant of Exfoliative-toxin-A+ S. aureus in an Adult Immunocompromised Woman.
Topics: Adenine; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Exfoliatins; Female; Humans; Immunoco | 2018 |
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
Topics: Adenine; Aged; Brain Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neuroaspergillo | 2018 |
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bacterial Infections; Electronic Health Records; Female; Hu | 2018 |
Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report.
Topics: Abdomen; Adenine; Aged; Fatal Outcome; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Ch | 2019 |
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.
Topics: Adenine; Adult; Aged; Aged, 80 and over; B-Lymphocytes; Female; Humans; Incidence; Male; Middle Aged | 2019 |
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2017 |
Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Ganciclovir; He | 1991 |
Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine.
Topics: Adenine; Animals; Antiviral Agents; Cats; Cell Line; HIV; Immunologic Deficiency Syndromes; Opportun | 1990 |
9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Antiviral Agents; Concanavalin A; Herpes Simpl | 1989 |